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CLINICAL SCIENCE
Effect of Cumulating Exposure to Abacavir on the Risk of
Cardiovascular Disease Events in Patients From the Swiss
HIV Cohort Study
Jim Young, PhD,* Yongling Xiao, PhD,†‡ Erica E. M. Moodie, PhD,‡ Michal Abrahamowicz, PhD,‡
Marina B. Klein, MD, MSc,§ Enos Bernasconi, MD, MSc,k Patrick Schmid, MD,¶
Alexandra Calmy, MD, PhD,# Matthias Cavassini, MD,** Alexia Cusini, MD,†† Rainer Weber, MD,‡‡
and Heiner C. Bucher, MD, MPH,*§§ the Swiss HIV Cohort Study
Background: Patients with HIV exposed to the antiretroviral drug
abacavir may have an increased risk of cardiovascular disease
(CVD). There is concern that this association arises because of
a channeling bias. Even if exposure is a risk, it is not clear how that
risk changes as exposure cumulates.
Methods: We assess the effect of exposure to abacavir on the risk
of CVD events in the Swiss HIV Cohort Study. We use a new
marginal structural Cox model to estimate the effect of abacavir as
a ﬂexible function of past exposures while accounting for risk factors
that potentially lie on a causal pathway between exposure to abacavir
and CVD.
Results: A total of 11,856 patients were followed for a median of 6.6
years; 365 patients had a CVD event (4.6 events per 1000 patient-
years). In a conventional Cox model, recent—but not cumulative—
exposure to abacavir increased the risk of a CVD event. In the new
marginal structural Cox model, continued exposure to abacavir during
the past 4 years increased the risk of a CVD event (hazard ratio = 2.06;
95% conﬁdence interval: 1.43 to 2.98). The estimated function for the
effect of past exposures suggests that exposure during the past 6–36
months caused the greatest increase in risk.
Conclusions: Abacavir increases the risk of a CVD event: the
effect of exposure is not immediate, rather the risk increases as
exposure cumulates over the past few years. This gradual increase in
risk is not consistent with a rapidly acting mechanism, such as acute
inﬂammation.
Key Words: HIV, antiretroviral therapy, reverse transcriptase
inhibitors, adverse effects, marginal structural models
(J Acquir Immune Deﬁc Syndr 2015;69:413–421)
INTRODUCTION
In 2008, an analysis by the D:A:D collaboration of
observational cohorts showed that recent exposure to the
antiretroviral drug abacavir was associated with an increased
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risk of cardiovascular disease (CVD) events.1 Subsequent
meta-analyses of randomized controlled trials failed to ﬁnd
evidence of this association.2–5 The D:A:D emphasized that
stopping smoking would do more to reduce the risk of a heart
attack than stopping abacavir and noted that the absolute risk
of such events was low.6 Nevertheless, their results caused an
unprecedented change in prescribing behavior.7
Neither cumulative nor past exposure to abacavir
seemed to increase the risk of these events,1 and the D:A:D
collaboration observed that while current use was a risk,
this risk seemed to reverse shortly after the use of abacavir
ceased.8 These factors led the collaboration to suggest that
a rapidly acting mechanism, such as vascular inﬂamma-
tion, could be responsible for the increase in risk.
However, subsequent biomarker studies proved inconclu-
sive9–12 and analyses of other observational cohorts led to
inconsistent results.9,10,13,14
There is also lingering concern that any association
between abacavir and CVD could be an artifact of either
“channeling bias” or the failure to adjust for potential
confounders such as renal function or injection drug use.9
Indeed, patients at higher risk of CVD were more likely to
receive abacavir1,15 (a “channeling bias”16 or “confounding
by indication”17). The D:A:D did not adjust for time-
varying risk factors such as blood lipid levels and
blood pressure because, if they lie on a causal pathway
between exposure to abacavir and CVD, adjusting for
them could “adjust away” the effect of interest.18 This
situation necessitates more complex methods of analysis;
marginal structural modeling19 in particular has been
recommended.18,20,21
In most analyses, it is not known how the effect of
exposure to a drug cumulates over time. Assuming a simple
relationship between exposure and outcome can erode the
power to detect a relationship and give a misleading picture
of how best to minimize the risk of an adverse event.22 We
assess the effect of exposure to abacavir on the risk of CVD
events in the Swiss HIV Cohort Study (SHCS). First, we
reproduce the D:A:D’s analysis using SHCS data; then, we
consider the likely results had they used more complex
statistical methods. We ﬁt a new marginal structural model23
to estimate the effect of abacavir as a ﬂexible function of
past exposures while accounting for risk factors that
potentially lie on a causal pathway between exposure to
abacavir and CVD.
METHODS
Patients
The SHCS is a prospective cohort with continuing
enrollment of HIV-infected adults.24 Since April 1, 2000,
a cardiovascular risk assessment has been a part of follow-up
visits scheduled every 6 months at 1 of 7 outpatient clinics or
at the ofﬁce of a collaborating physician. At each assessment,
blood pressure, smoking status, weight, and body fat loss or
gain are recorded, and a blood sample is taken to measure
blood lipids. In this study, we include all patients with at least
1 cardiovascular risk assessment.
Outcome, Covariate, and
Exposure Definitions
We consider a composite outcome to maximize the
number of suitable disease events. As in the D:A:D study,1 we
deﬁne a CVD event as the ﬁrst occurrence of either
a myocardial infarction, an invasive cardiovascular procedure
or a cardiovascular-related death. Each myocardial infarction
or invasive cardiovascular procedure was documented in
a checking chart25; since 2005, each death has been
documented using a cause of death form.26,27
As in the D:A:D study, each patient’s follow-up is
divided into consecutive 1-month periods in our analyses. To
reproduce the D:A:D’s analysis, we adjust for the same
covariates in our conventional multivariate models. Hence,
these models have time-ﬁxed covariates for demographic
characteristics (age, sex, likely transmission through injection
drug use, Caucasian ethnicity), calendar year, and CVD risk
factors (family history of coronary heart disease, previous
CVD event); and time-varying covariates for CVD risk factors
(smoking status and body mass index, updated each follow-up
visit) and cumulative exposure to 15 other antiretroviral drugs
(with a separate covariate for each drug updated each month).
Time-varying covariates identiﬁed by the D:A:D as
potentially on a causal pathway between exposure to abacavir
and CVD are not included in our conventional multivariate
models but are accounted for in our marginal structural Cox
models. These covariates are represented by separate indica-
tors for hypertension, dyslipidemia, and diabetes (and in
a sensitivity analysis, an indicator for chronic kidney disease);
indicators for 3 Framingham risk score categories28; and
continuous measures of CD4 cell count and log 10 HIV RNA
(viral load).
When estimating the effect of abacavir as a ﬂexible
function of past exposures, exposure is represented by an
indicator variable with value 1 if the patient was taking
abacavir on the ﬁrst day of the month. Other estimates of the
effect of abacavir use exposure indicators and duration of
exposure as at the ﬁrst day of the month derived from the
exact dates the patient started and stopped taking abacavir.
Statistical Analyses
We analyze time to the ﬁrst CVD event using various
forms of the Cox proportional hazard model. For each patient,
follow-up begins at their ﬁrst CVD risk assessment. A patient
with no CVD event during follow-up is censored at a death
unrelated to CVD, 6 months after their last CVD assessment
if lost to follow-up or at the end of the study (30 September,
2012), whichever comes ﬁrst. As in the D:A:D’s analyses, we
assume that censoring is uninformative.
Conventional Modeling
We ﬁt 3 conventional Cox models; all adjust for the
same covariates, but the history of exposure to abacavir is
represented in different ways. The ﬁrst model reproduces an
analysis reported by the D:A:D, with 2 time-varying exposure
variables: one for the total duration of past use (cumulative
use) and the other an indicator of any exposure within the
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previous 6 months (recent use). The other 2 conventional
models use exposure variables suggested by the results of our
cumulative exposure modeling. These results suggest that
current exposure to abacavir might be protective and that
exposure during the past 6–36 months causes the greatest
increase in the risk of a CVD event. Hence, the second model
has 3 exposure variables: cumulative use as before, but with
recent use partitioned into 2 indicators, use in the current
month, and use in the previous 1 to 6 months. The third model
has exposure to abacavir represented by 3 variables: current
use, use in the previous 1 to 6 months, and the total duration
of use over the past 7–36 months.
Marginal Structural Modeling
We also ﬁt the models described above as marginal
structural Cox models using stabilized inverse probability of
treatment weights (see Section 1, Supplemental Digital
Content, http://links.lww.com/QAI/A680). This process re-
quires 8 different logistic regression models to estimate the
probability that in a given month a patient either starts
treatment with abacavir (if abacavir-naive) or continues
treatment with abacavir (if already exposed) given the most
recent values of confounding variables. The process also
allows relationships between confounding variables and
treatment to change after February 2008 because prescribing
behavior changed after the D:A:D’s results were
published.7,29
Cumulative Exposure Modeling
We ﬁt a new marginal structural model that estimates the
effect of abacavir as a ﬂexible function of past exposure while
using the same inverse probability of treatment weights as
above.23 Exposure to abacavir is deﬁned as a weighted sum of
use in each past month, with (exposure) weights found by
estimating a cubic spline for the relative importance of
exposure at different times in the past. We assume that
exposure more than 4 years ago would have no effect on the
current risk of a CVD event. We consider 9 alternative
weight functions (see Section 2, Supplementary Digital
Content, http://links.lww.com/QAI/A680); these differ in their
degree of ﬂexibility and in whether weights are forced to take
zero value at both the beginning and end of the 4-year interval,
or just at the end of 4 years, or can take values other than zero at
all times. A zero weight at the beginning of the 4-year interval
implies that there is a lag between exposure and its effect on the
current risk of an event. Having selected the best ﬁtting weight
function,30 we estimate a hazard ratio (HR) comparing 2
different treatment strategies—always exposed to abacavir over
the entire 4 years versus never exposed over this period.
Additional Analyses
We reﬁt our weighted models with a time-varying
indicator of chronic kidney disease added to the covariates used
to calculate inverse probability of treatment weights (see Section
3, Supplemental Digital Content, http://links.lww.com/QAI/
A680). This sensitivity analysis requires a truncated data set,
limited to follow-up after January 2002 when routine serum
creatinine measurement began in the SHCS.31 We deﬁne chronic
kidney disease as an estimated glomerular ﬁltration rate (calcu-
lated using CKD-EPI equation32) below 60 mL/min per 1.73 m2.
In 2 unplanned sensitivity analyses, we reﬁt models
for abacavir after excluding patients infected with HIV
through injection drug use and after excluding patients
exposed to abacavir before their ﬁrst cardiovascular
risk assessment (see Section 4, Supplemental Digital Content,
http://links.lww.com/QAI/A680). The second analysis avoids
a bias that would arise if existing uses of abacavir were in
a sense “survivors” at low risk of CVD,33 and its population of
abacavir-naive patients corresponds to the “full population” used
in a recent analysis by the NA-ACCORD.34
We also perform a set of analyses for 2 other
antiretroviral drugs from the same drug class: didanosine
and tenofovir (see Sections 5 and 6, Supplemental Digital
Content, http://links.lww.com/QAI/A680). The D:A:D col-
laboration found that recent exposure to didanosine was
also associated with an increased risk of CVD events.1
Didanosine and abacavir are both guanosine analogs and
hence might plausibly have similar effects. However,
tenofovir was not associated with an increased risk of
CVD events, although subject to the same channeling
biases as abacavir.35
RESULTS
Patients
As at October 2012, 11,924 patients in the SHCS had at
least 1 cardiovascular risk assessment, and 11,856 patients
provided follow-up with all covariates available. These
11,856 patients have been followed for a total of 80,004
patient-years with a median follow-up of 6.6 years [inter-
quartile range (IQR), 2.8–11.6]. Of these patients, 1549 were
exposed to abacavir before assessments began, for a median
duration of 0.7 years (IQR, 0.2–1.4). During follow-up, 4052
patients were exposed to abacavir, for a median duration of
3.4 years (IQR, 1.3–6.0), and of these, 2297 stopped taking
abacavir during follow-up and 821 restarted again. During
follow-up, 365 patients had a CVD event (3.0%); of these,
195 had been exposed to abacavir (53%), for a median
duration of 3.4 years (IQR, 1.0–5.9). Half of the CVD events
included a myocardial infarction (Table 1). Of the 11,491
patients without a CVD event, 4312 had been exposed to
abacavir (38%), for a median duration of 3.3 years (IQR, 1.0–
6.0). Patients who had a CVD event were older and more
likely to be men, currently smoking, with a previous CVD
event, or a family history of such events (Table 1). They were
also more likely to have diabetes, chronic kidney disease,
hypertension, dyslipidemia, or lipodystrophy and had higher
Framingham risk scores than those without an event.
Conventional and Marginal
Structural Modeling
In our ﬁrst conventional model (Table 2), the risk of
a CVD event increased with recent exposure to abacavir [HR =
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1.50; 95% conﬁdence interval (CI): 1.12 to 2.00] with weaker
evidence of an increase with greater cumulative exposure (HR =
1.04; 95% CI: 0.99 to 1.10, per year). These estimates are close
to the equivalent estimates reported by the D:A:D (HR = 1.63;
95% CI: 1.30 to 2.04, for recent exposure and HR = 1.03; 95%
CI: 0.96 to 1.10, per year for cumulative exposure1).
The other 2 conventional models use exposure variables
suggested by the results of our cumulative exposure modeling
(Table 2, footnotes). The ﬁrst of these 2 models suggests that
recent exposure in the past zero to 6 months can be
partitioned into current exposure and recent exposure in the
previous 1 to 6 months. In this second model, current
exposure has a protective effect (HR = 0.36; 95% CI: 0.23
to 0.55), whereas recent exposure increases the risk of a CVD
event (HR = 3.69; 95% CI: 2.36 to 5.75) such that the mixing
of current and recent exposure in the ﬁrst model understates
TABLE 1. Characteristics of Patients at the Time of Their First CVD Event or If No Such Event, at Their Last Follow-up Visit—Median
or Proportion
Characteristic
Patients With a CVD Event
Patients Without
a CVD EventAll
Exposed to Antiretroviral Therapy*
Exposed to Abacavir Exposed to Didanosine Exposed to Tenofovir
General
Number of patients 365 195 151 148 11,491
Male 0.83 0.83 0.81 0.83 0.70
Age, yrs 45 44 46 44 35
CD4 cell count, cells/mL 470 500 460 460 510
Suppressed viral load† 0.76 0.80 0.75 0.82 0.76
Body mass index .26, kg/m2 0.25 0.23 0.22 0.26 0.26
Current smoker 0.61 0.58 0.59 0.61 0.47
Ex-smoker 0.21 0.22 0.22 0.25 0.21
Infected through injection drug use 0.22 0.22 0.24 0.26 0.19
CVD
Previous event‡ 0.14 0.12 0.13 0.12 0.01
Family history§ 0.19 0.16 0.20 0.18 0.11
Diabetes mellitusk 0.15 0.15 0.15 0.17 0.06
Chronic kidney disease¶ 0.21 0.17 0.21 0.11 0.09
Hypertension
Use of antihypertensive medication 0.43 0.43 0.36 0.45 0.18
Arterial hypertension# 0.59 0.61 0.54 0.64 0.34
Lipid levels
Total cholesterol, mmol/L 5.4 5.5 5.6 5.4 4.9
HDL cholesterol, mmol/L 1.1 1.1 1.1 1.1 1.2
Use of lipid-lowering medication 0.32 0.32 0.35 0.33 0.10
Dyslipidemia** 0.65 0.63 0.68 0.62 0.36
Lipodystrophy†† 0.45 0.46 0.54 0.48 0.27
Framingham risk score‡‡
Low (,10%) 0.40 0.41 0.42 0.40 0.76
Moderate (10%–20%) 0.45 0.43 0.42 0.47 0.21
High (.20%) 0.15 0.17 0.15 0.14 0.03
CVD event§§
Myocardial infarction 0.51 0.56 0.57 0.47 NA
Invasive cardiovascular procedurekk 0.72 0.72 0.72 0.76 NA
Cardiovascular death 0.12 0.10 0.14 0.08 NA
*Patients could be exposed to none of these 3 drugs or to 1 or more.
†HIV RNA undetectable or below 50 copies per milliliter.
‡CVD event before the patients ﬁrst cardiovascular risk assessment.
§Myocardial infarction or stroke before the age of 50 in any ﬁrst degree relative.
kClinical diagnosis, or casual plasma glucose .11.1 mmol/L, or on antidiabetic medication or insulin.
¶Estimated glomerular ﬁltration rate (calculated using CKD-EPI equation32) ,60 mL/min per 1.73 m2.
#Systolic blood pressure .140 mm Hg, diastolic blood pressure .90 mm Hg, or on antihypertensive medication.
**Total cholesterol .6.2 mmol/L, high-density lipoprotein (HDL) cholesterol ,0.9 mmol/L, or on lipid-lowering medication.
††Patient and clinician report either body fat loss or body fat gain.
‡‡Estimated risk of CVD in the next 10 years.
§§More than 1 event can occur during the same month.
kkCoronary angioplasty/stenting, coronary artery by-pass grafting, carotid endarterectomy, procedures on other arteries.
NA, not applicable.
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the risk posed by the latter. The third model suggests that
cumulative exposure during the past 7 months to 3 years (HR =
1.25; 95% CI: 1.04 to 1.51, per year) does indeed increase the
risk of a CVD event, as predicted by our cumulative exposure
modeling. Reﬁtting these 3 models as marginal structural
models led to very similar estimates (Table 2).
Cumulative Exposure Modeling
Of the 9 exposure weight functions, the best ﬁtting weight
function had a single knot and weights of zero at both the
beginning and end of the 4-year interval (Fig. 1, left). This
function implies that exposure to abacavir did not immediately
increase the current risk of a CVD event; rather this risk reﬂects
cumulating exposure to abacavir over the past 6–36 months. Of
note, weight functions where the effect of current exposure
could have a weight other than zero had negative weights for the
earliest months of the interval suggesting that current exposure
might have a protective effect (see Section 2, Supplemental
Digital Content, http://links.lww.com/QAI/A680). The total
effect of always being exposed to abacavir, during the entire
4-year period, versus never being exposed was HR = 2.06,
95% CI: 1.43 to 2.98 (Fig. 1, right). Cumulative exposure
modeling without inverse probability weights gave a similar
estimate of this total effect (HR = 2.10; 95% CI: 1.58 to 2.78;
Fig. 1, right).
Additional Analyses
Estimates of the effect of abacavir were not attenuated
when an indicator for chronic kidney disease was added to the
covariates used to calculate inverse probability of treatment
weights. Estimates of the effect of abacavir were not attenuated
in unplanned analyses of patients not infected through injection
drug use and of abacavir-naive patients. Cumulative exposure
modeling suggested exposure to didanosine had early harmful
and then later protective effects (Fig. 2), whereas exposure to
tenofovir had if anything a protective rather than a harmful
effect (Fig. 3). Results for these additional analyses are
summarized in Sections 3–6 of the Supplemental Digital
Content (http://links.lww.com/QAI/A680).
DISCUSSION
Our results suggest that the risk of a CVD event
increases as past exposure to abacavir cumulates, but only for
a limited period. Exposure during the past 6–36 months
causes the greatest increase in risk; both current exposure and
exposure more than 3 years ago cause little additional
increase in risk. Acute inﬂammation has been suggested as
an explanation for the increase in CVD risk with exposure to
abacavir because the risk seemed associated with recent and
not past exposure.1,8 Our results suggest that other explan-
ations should be sought because the increase in risk is not
immediate and it cumulates so that past exposure within the
last 3 years still inﬂuences current risk.
Note that the relative risks presented in Table 2 should
not be interpreted too literally. The models in this table
illustrate how different partitions of time—into current, recent,
or cumulative use—can lead to different clinical conclusions.
Our estimated weight function (Fig. 1, left) does not require
this arbitrary partitioning and is therefore a more reliable basis
for drawing clinical conclusions. Having estimated this weight
function, a contrast between any 2 treatment histories can be
generated, and we show one contrast of obvious interest—the
TABLE 2. Relative Risk of a CVD Event for Patients Exposed to Abacavir
Exposure Parameters
Conventional Model* Marginal Structural Model†
Hazard Ratio 95% CI Hazard Ratio 95% CI
Model 1‡
Cumulative exposure (per year) 1.04 0.99 to 1.10 1.04 0.97 to 1.10
Recent exposure within past 0–6 mo 1.50 1.12 to 2.00 1.63 1.14 to 2.32
Model 2§
Cumulative exposure (per year) 1.05 1.00 to 1.10 1.05 0.98 to 1.11
Recent exposure within past 1–6 mo 3.69 2.36 to 5.75 4.61 2.59 to 8.23
Current exposure 0.36 0.23 to 0.55 0.28 0.15 to 0.50
Model 3k
Cumulative exposure within the past 7–36 mo (per
year)
1.25 1.04 to 1.51 1.22 0.98 to 1.52
Recent exposure within past 1–6 mo 3.20 1.97 to 5.19 4.06 2.24 to 7.34
Current exposure 0.35 0.22 to 0.54 0.27 0.15 to 0.50
*Models adjusted for age, sex, likely transmission through injection drug use, Caucasian ethnicity, family history of coronary heart disease, previous CVD event, smoking status,
body mass index, calendar year, and cumulative exposure to 15 other antiretroviral drugs.
†Models ﬁt using inverse probability weights, with weights found using 8 different logistic regression models. The covariates in these models included those used in the
conventional models plus indicators for hypertension, dyslipidemia, diabetes, Framingham risk score categories, and continuous measures of CD4 cell count and log 10 HIV RNA.
‡Model 1 reproduced an analysis reported by the D:A:D—their estimates were HR = 1.03, 95% CI: 0.96 to 1.10, per year for cumulative exposure and HR = 1.63, 95% CI: 1.30 to
2.04, for recent exposure.1
§Model 2 was suggested by cumulative exposure modeling—weight functions where the effect of current exposure could have a weight other than zero had negative weights for
the earliest months of the 4-year interval suggesting that current exposure had a protective effect.
kModel 3 was suggested by cumulative exposure modeling—the best ﬁtting weight function (Fig. 1, left) suggested that cumulating exposure to abacavir over the past 6–36 months
causes the greatest increase in the risk of a CVD event.
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effect of always being exposed to abacavir, over a 4-year
period, versus never being exposed (Fig. 1, right).
With our data, we were able to reproduce estimates
reported by the D:A:D despite the changes in prescribing
behavior brought about by the publication of their results.
Although the SHCS contributes data to the D:A:D, only 45%
of our 365 events occurred before February 2007 and might
therefore have been included in their original analysis. The
results of our cumulative exposure modeling explain seemingly
inconsistent results from earlier studies. If the harmful effects
of exposure cumulate but only for a ﬁnite period, and yet
patients are exposed to abacavir for much longer, cumulative
exposure per year will seem weakly harmful at the best.13,35
Exposure to abacavir more than 6 months earlier may well
seem harmful, although studies may lack the power to really
conﬁrm or rule out such an effect.1,37 Recent use should seem
harmful, as it has in many studies,1,14,35,37 but may underesti-
mate the short-term risk if current use is included in the
deﬁnition of recent use because current use seems protective.13
An early protective effect could arise because abacavir, as
part of an effective therapy, reduces viral replication, a risk factor
for CVD events,38,39 or because of a “reverse causation bias”40 if
patients at high risk of a CVD event were taken off abacavir after
only a short exposure but then went on to have such an event.
Our modeling suggests that after the D:A:D’s results were
published, patients with a previous CVD event or a high
Framingham risk score were taken off abacavir (see Section 1,
Supplemental Digital Content, http://links.lww.com/QAI/A680).
But, of the 53 high-risk patients who stopped taking abacavir
after February 2008, only 2 went on to have a CVD event and
both had at least 5 years of exposure to abacavir.
This change in prescribing behavior was considered
prudent.9 However, for patients who smoke, giving up
smoking leads to a greater reduction in CVD risk than
avoiding exposure to abacavir.6,41 For many patients, the
increase in relative risk with exposure to abacavir will be
acceptable, if other risk factors for CVD are absent,42 given
the low rate of CVD events—4.6 per 1000 patient-years in
FIGURE 1. The effect of exposure to
abacavir on the risk of CVD events:
the estimated weight function (left)
and the estimated total cumulative
effect (as an HR) of always being
treated with abacavir over the past
48 months versus never being trea-
ted with abacavir (right). Exposure
more than 4 years ago was assumed
to have no effect on current risk.
Functions are shown for cumulative
exposure modeling with both mar-
ginal structural (solid curve) and
conventional (dashed curve) Cox
models.23,36 Of the 9 alternative
weight functions considered, the
best fitting weight function had
a single knot and (exposure) weights
of zero at both the beginning and
end of the 4-year interval.
FIGURE 2. The effect of exposure to
didanosine on the risk of CVD
events: the estimated weight func-
tion (left) and the estimated total
cumulative effect (as an HR) of
always being treated with didano-
sine over the past 30 months versus
never being treated with didanosine
(right). Exposure more than 30
months ago was assumed to have
no effect on current risk. Functions
are shown for cumulative exposure
modeling with both marginal struc-
tural (solid curve) and conventional
(dashed curve) Cox models.23,36 Of
the 9 alternative weight functions
considered, the best fitting weight
function had a single knot and
(exposure) weights of zero at both
the beginning and end of the
30-month interval.
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these data—and that alternatives such as tenofovir also have
side effects.31,43 The question of whether—and how—abacavir
increases the risk of CVD is still important. The recently
approved coformulation of dolutegravir, a new integrase
inhibitor, with abacavir and lamivudine provides a 1 pill once
a day regimen once a day regimen that is likely to prove
popular with patients.44,45 Integrase inhibitors are well-tolerated
antiretrovirals because they do not interfere with normal
cellular processes46 and are therefore considered suitable for
patients at risk of CVD.47
Strengths of this study include that this is an analysis of
data from a single cohort. This avoids the additional variation
that arises when contributing cohorts in a multicohort collabo-
ration use different methods to collect and measure data. Our CIs
for estimates of effect sizes are of a similar width to those
reported in the D:A:D’s original study,1 yet in our data, we have
only half the number of CVD events (365 versus 693 events).
We use modeling that does not require strong assumptions about
the relationship between exposure and outcome. As a conse-
quence, in our results, we see a relationship between exposure to
abacavir and the risk of CVD events that is both plausible—in
that risk lags exposure and does not cumulate indeﬁnitely—and
explains seemingly inconsistent results from earlier studies.
Finally, unlike other observational studies, our analyses also
account for covariates potentially on a causal pathway between
exposure to abacavir and CVD; this reduces the residual
confounding that would otherwise arise when those exposed
to abacavir are at greater risk of CVD than the unexposed.18
Note that estimates in Table 2 with and without marginal
structural modeling are similar, vindicating those who main-
tained that such modeling would not have altered the con-
clusions of their analyses.1,29,35 However, marginal structural
modeling was important in our analysis of tenofovir (Fig. 3).
We note the following study limitations. As in the D:A:D
study,1 not all patients were abacavir-naive at the start of follow-
up, with 13% of patients pre-exposed. Those pre-exposed to
abacavir had a higher prevalence of dyslipidemia and of
moderate or high Framingham risk scores (data not shown),
but our modeling of continued use of abacavir took such factors
into account. A causal interpretation of our results is only
possible if there is no unmeasured confounding.19 We did not
adjust for time-dependent injection drug use because routine
recording of this only began in July 2008. Note, however, that
sensitivity analyses of abacavir-naive patients and of patients not
infected through injection drug use gave similar results to the
main analysis. We did not have sufﬁcient events to warrant
cumulative exposure modeling of the risk of myocardial
infarction alone (Table 1).
The implication of these results is that a rapidly acting
mechanism, such as acute inﬂammation,1,8 may not be
responsible for the increased risk of CVD with exposure to
abacavir. A possible early protective effect and a later
cumulative harmful effect suggest more gradual processes.
One possibility for a cumulative harmful effect is mitochon-
drial toxicity,48 as abacavir may interact with cytidine analogs
lamivudine and emtricitabine.49 The heart, with its high
metabolic demand, is rich in mitochondria and is susceptible
to mitochondrial damage, especially as it ages.50 Several
mechanisms could be involved: equivalent modeling of the
risk of CVD with exposure to didanosine suggests that the 2
drugs may affect CVD in different ways. Our results for
didanosine suggest an unexpected dual effect—a rapid early
harmful effect followed by a later protective effect (Fig. 2).
This might explain why other studies show that recent
exposure to didanosine is harmful but that cumulative exposure
has no net effect1,35 or even a protective effect.37 In the updated
D:A:D analysis, plots showing the rate of myocardial infarction
with cumulative exposure are consistent with what we report
here—with abacavir, the rate increases and then levels off after 2
to 3 years of exposure; with didanosine, the rate seems to peak
after about 1 to 2 years of exposure and may then decline.35
Our results suggest a number of directions for future
research. First, one could reconsider more gradual processes
that might give rise to an increasing risk of CVD with
cumulating exposure to abacavir. Second, one could look for
evidence of a protective effect with current exposure to
abacavir in data collected before the D:A:D’s results promp-
ted clinicians to take high risk patients off abacavir. Third,
FIGURE 3. The effect of exposure to
tenofovir on the risk of CVD events:
the estimated weight function (left)
and the estimated total cumulative
effect (as an HR) of always being
treated with tenofovir over the past
48 months versus never being trea-
ted with tenofovir (right). Exposure
more than 4 years ago was assumed
to have no effect on current risk.
Functions are shown for cumulative
exposure modeling with both mar-
ginal structural (solid curve) and
conventional (dashed curve) Cox
models.23,36 Of the 9 alternative
weight functions considered, the
best fitting weight function had
a single knot and (exposure) weights
of zero at both the beginning and
end of the 4-year interval.
J Acquir Immune Defic Syndr  Volume 69, Number 4, August 1, 2015 Abacavir and CVD
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. www.jaids.com | 419
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
one could consider whether the harmful effects of abacavir
and didanosine might involve substantially different pro-
cesses. Although our analyses suggest that exposure to
abacavir increases the risk of CVD, they also suggest that
acute processes are unlikely to be the cause.
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